Bryce Cooper

Bryce has significant experience in all aspects of litigation in federal and state courts from discovery through trial and appeal. Notable representations include:

• Currently representing global health care company in mass torts litigation alleging that cow milk-based infant formula products cause a naturally occurring gastrointestinal disorder in premature infants.
• Currently representing a chemical manufacturer against environmental and products liability claims alleging groundwater contamination and personal injury.
• Obtained a jury trial victory in favor of a medical device manufacturer in products liability action alleging design defect, manufacturing defect, failure to warn, and negligence claims related to a breakthrough cardiac artery stenting product.
• Obtained two trial victories for generic pharmaceutical company establishing noninfringement of patents that blocked generic competition for Cabometyx® (cabozantinib), a cancer treatment drug. The trial victory may allow generic versions of the drug to launch years before the patents-in-suit would have expired.
• Obtained a trial victory for generic pharmaceutical companies invalidating four patents that blocked generic competition for the drug Ampyra® (dalfampridine), which improves walking in patients with multiple sclerosis. The trial victory and affirmance at the Federal Circuit allows generic versions of the drug to launch almost a full decade before the patents-in-suit would have expired.
• Represented Monsanto Company in the first Roundup® product liability and failure-to-warn case to go to trial in the country. Following an eight-week jury trial, the trial team successfully reduced a punitive damages award by US$211 million, and the verdict was further reduced on appeal. Obtained dismissal of another Roundup® suit before trial. 
• Obtained a jury trial victory for a global ingredients and ethanol producer in an action for fraudulent inducement against an equipment provider that claimed to have developed a proprietary and revolutionary technology for use in the production of ethanol. After a three-week trial, a New York County jury rejected the equipment manufacturer’s US$180 million damages claim and instead awarded our client rescission of the license agreement and the return of its licensing payments.
• Defeated a bellwether case claiming that food ingredient manufacturers were liable for plaintiff’s overconsumption of sweetened foods and resulting health that Forbes described as “the most notorious illustration of how a baseless lawsuit can effectively demonize one disfavored food ingredient.”
• Represented an airplane manufacturer in a series of products liability actions alleging toxic air exposure.
• Represented a medical device manufacturer in numerous products liability actions alleging design defect, manufacturing defect, failure to warn, and negligence claims related to cardiac guide wire products.
• Represented manufacturers of high fructose corn syrup in a high-profile false advertising matter brought by members of the sugar industry. The suit challenged the freedom of the corn refiners to educate the public about high fructose corn syrup.
• Represented dental trade associations in their defense of antitrust and business tort claims brought by a competing trade association, obtaining victory on a motion to dismiss.
• Represented Seven Seas Partnership Limited, a film financing company, in its breach of contract suit brought against Terrence Malick’s production company for failure to timely complete the feature film, Voyage of Time.

Bryce’s representation of generic pharmaceutical companies against claims of patent infringement span a variety of drug products including Lidoderm®, Entocort®, Metadate CD®, Remodulin®, Ampyra®, Istodax®, Tyvaso® Orenitram®, Linzess®, Myrbetriq®, Hetlioz®, Invokana®, Invokamet XR®, Jardiance®, Glyxambi®, Synjardy XR®, Cabometyx®, Briviact®, and Ocaliva®.